ReviewInfectious disease clinics of North America2011
Interferons as therapeutic agents for infectious diseases.
Review in Infectious disease clinics of North America, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Safety, Tolerability, Bioavailability, and Biological Activity of Inhaled Interferon-α2b in Healthy Adults: The INClinical drug investigation · 2023Trial
- HCV-specific immune responses induced by CIGB-230 in combination with IFN-α plus ribavirin.World journal of gastroenterology · 2014Trial
- Review
- Protein quality control and antigen presentation in the development of hepatitis B-related hepatocellular carcinoma.Frontiers in pharmacology · 2026Review
- Global trends and insights in interferon therapy for chronic hepatitis B: a bibliometric analysis.Virology journal · 2025Article
- Affordable mRNA Novel Proteins, Recombinant Protein Conversions, and Biosimilars-Advice to Developers and Regulatory Agencies.Biomedicines · 2025Review
- Site-Specific Glyco-Tagging of Native Proteins for the Development of Biologicals.Journal of the American Chemical Society · 2024Article
- Advancing Therapeutic and Vaccine Proteins: Switching from Recombinant to Ribosomal Delivery-A Humanitarian Cause.International journal of molecular sciences · 2024Review
- A hybrid method for discovering interferon-gamma inducing peptides in human and mouse.Scientific reports · 2024Article
- The balance between gasdermin D and STING signaling shapes the severity of schistosome immunopathology.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Synthesis, Characterization, and Antiproliferative Effect of CuO-TiOBioinorganic chemistry and applications · 2022Article
- Nanotechnology advances in pathogen- and host-targeted antiviral delivery: multipronged therapeutic intervention for pandemic control.Drug delivery and translational research · 2021Review
- Review: The Nose as a Route for Therapy. Part 2 Immunotherapy.Frontiers in allergy · 2021Review
- COVID-19 in China: From epidemiology to treatment (Review).Experimental and therapeutic medicine · 2020Review
- High yield soluble bacterial expression and streamlined purification of recombinant human interferon α-2a.Protein expression and purification · 2014Article
- Overexpression of Recombinant Human Beta Interferon (rhINF-β) in Periplasmic Space of Escherichia coli.Iranian journal of pharmaceutical research : IJPR · 2014Article
- Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry.BMC microbiology · 2013Article
- MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment.The Journal of general virology · 2013Article
- Identification of small molecules with type I interferon inducing properties by high-throughput screening.PloS one · 2012Article
- Clinical Evaluation of Terap C Vaccine in Combined Treatment with Interferon and Ribavirin in Patients with Hepatitis C.Current therapeutic research, clinical and experimentalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article explains the rationale for development of interferons as therapeutic agents, and describes commercial products available today. It also provides a summary of studies that have been performed with interferons for use as exogenous biological response modifiers in viral infections. Overall, the best data exist for treatment of viral hepatitis B and C, for which interferons are a cornerstone of therapy. Although infections with human papillomavirus and common cold viruses sometimes respond favorably to interferons, their outcomes are far from ideal. Finally, the role of interferons as vaccine adjuvants is still being explored but could be promising.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.